Isofol continues to ramp up patient recruitment and reiterates the plans to expand the AGENT trial to new markets. Further, the company reports that they are carrying out activities to increase the awareness of arfolitixorin in the scientific community and among potential partners. In conjunction with the report, it was announced that Anders Rabbe will step down of Isofol and that the chairman of the board, Dr Jarl Ulf Jungnelius, M.D., is appointed as the new CEO.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se